AIM: To investigate whether composite yogurt with acacia dietary fiber and Bifidobacterium lactis (B. lactis) has additive effects in irritable bowel syndrome (IBS). METHODS: A total of 130 patients were randomly allocated to consume, twice daily for 8 wk, either the composite yogurt or the control product. The composite yogurt contained acacia dietary fiber and high-dose B. lactis together with two classic yogurt starter cultures. Patients were evaluated using the visual analog scale via a structured questionnaire administered at baseline and after treatment. RESULTS: Improvements in bowel habit satisfaction and overall IBS symptoms from baseline were significantly higher in the test group than in the control group (27.16 vs 15.51, P = 0.010, 64.2 ± 17.0 vs 50.4 ± 20.5, P < 0.001; respectively). In constipation-predominant IBS, improvement in overall IBS symptoms was significantly higher in the test group than in the control group (72.4 ± 18.4 vs 50.0 ± 21.8, P < 0.001). In patients with diarrhea-predominant IBS, improvement in bowel habit satisfaction from baseline was significantly higher in the test group than in the control group (32.90 vs 7.81, P = 0.006). CONCLUSION: Our data suggest that composite yogurt enriched with acacia fiber and B. lactis has greater therapeutic effects in patients with IBS than standard yogurt.
RCT Entities:
AIM: To investigate whether composite yogurt with acacia dietary fiber and Bifidobacterium lactis (B. lactis) has additive effects in irritable bowel syndrome (IBS). METHODS: A total of 130 patients were randomly allocated to consume, twice daily for 8 wk, either the composite yogurt or the control product. The composite yogurt contained acacia dietary fiber and high-dose B. lactis together with two classic yogurt starter cultures. Patients were evaluated using the visual analog scale via a structured questionnaire administered at baseline and after treatment. RESULTS: Improvements in bowel habit satisfaction and overall IBS symptoms from baseline were significantly higher in the test group than in the control group (27.16 vs 15.51, P = 0.010, 64.2 ± 17.0 vs 50.4 ± 20.5, P < 0.001; respectively). In constipation-predominant IBS, improvement in overall IBS symptoms was significantly higher in the test group than in the control group (72.4 ± 18.4 vs 50.0 ± 21.8, P < 0.001). In patients with diarrhea-predominant IBS, improvement in bowel habit satisfaction from baseline was significantly higher in the test group than in the control group (32.90 vs 7.81, P = 0.006). CONCLUSION: Our data suggest that composite yogurt enriched with acacia fiber and B. lactis has greater therapeutic effects in patients with IBS than standard yogurt.
Authors: A Agrawal; L A Houghton; J Morris; B Reilly; D Guyonnet; N Goupil Feuillerat; A Schlumberger; S Jakob; P J Whorwell Journal: Aliment Pharmacol Ther Date: 2008-09-17 Impact factor: 8.171
Authors: D Guyonnet; O Chassany; P Ducrotte; C Picard; M Mouret; C-H Mercier; C Matuchansky Journal: Aliment Pharmacol Ther Date: 2007-08-01 Impact factor: 8.171
Authors: H J Kim; M Camilleri; S McKinzie; M B Lempke; D D Burton; G M Thomforde; A R Zinsmeister Journal: Aliment Pharmacol Ther Date: 2003-04-01 Impact factor: 8.171
Authors: Bruno K Rodiño-Janeiro; María Vicario; Carmen Alonso-Cotoner; Roberto Pascua-García; Javier Santos Journal: Adv Ther Date: 2018-03-01 Impact factor: 3.845
Authors: Mohd Fyzal Bahrudin; Rafiz Abdul Rani; Azmi Mohd Tamil; Norfilza Mohd Mokhtar; Raja Affendi Raja Ali Journal: Dig Dis Sci Date: 2019-06-17 Impact factor: 3.199
Authors: Mohammad M H Abdullah; Collin L Gyles; Christopher P F Marinangeli; Jared G Carlberg; Peter J H Jones Journal: Food Nutr Res Date: 2015-12-11 Impact factor: 3.894